2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119146
    Zolazepam 31352-82-6 98%
    Zolazepam (CI-716 free base) is a benzodiazepine derivative with anxiolytic and anticonvulsant properties. Zolazepam combined with Tiletamine causes a decrease in ventilation, resulting in the development of respiratory acidosis. Zolazepam can be used as sedative and muscle relaxants.
    Zolazepam
  • HY-119174
    MK771 66537-55-1 98%
    MK771 is a thyrotrophin-releasing hormone analog. MK771 induces blinking and forepaw licking. MK771 has the potential for the research of morphine abstinence syndrome.
    MK771
  • HY-119211
    LY 97241 72456-63-4 98%
    LY 97241 accelerates the apparent rate of inactivation of transient outward K current. LY 97241 is an antiarrhythmic drug.
    LY 97241
  • HY-119232
    GSK466317A 864082-48-4 98%
    GSK466317A is a PKA inhibitor, with an IC50 of 12.59 μM. GSK466317A also inhibits GRK1, GRK2, and GRK5, with IC50s of 1000, 31.62, and 39.81 μM, respectively.
    GSK466317A
  • HY-119256
    COR627 329221-34-3 98%
    COR627 is a GABA receptor positive allosteric modulator with the ability to enhance GABA activity. COR627 exhibits effects on GABA and baclofen stimulation in rat cortical membranes and can increase its affinity for GABA(B) receptors. In vivo experiments have shown that COR627 can enhance the sedative/hypnotic effects of baclofen at pretreatment ineffective doses.
    COR627
  • HY-119274
    BN-82451 dihydrochloride 663172-95-0 98%
    BN-82451 dihydrochloride, an orally active and CNS-penetrated antioxidant and a multitargeting neuroprotective agent, exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis.
    BN-82451 dihydrochloride
  • HY-119277
    CJB-090 dihydrochloride 595584-40-0 98%
    CJB-090 dihydrochloride is a partial agonist with activity at dopamine D3 receptors. CJB-090 exhibits partial agonist characteristics in vitro. CJB-090 elicits yawning responses only in monkeys with an extensive history of cocaine use. CJB-090 reduces the reinstatement effects of cocaine in reinstatement behaviors induced by cocaine.
    CJB-090 dihydrochloride
  • HY-119336
    Mebroqualone 4260-20-2 98%
    Mebroqualone is structurally categorized as a quinazolinone.
    Mebroqualone
  • HY-119352
    S-2 Methanandamide 157182-48-4 98%
    S-2 Methanandamide is a potent CB1 receptor agonist, with IC50 values of 173 nM (with PMSF) and 8216 nM for CB1 and CB2, respectively.
    S-2 Methanandamide
  • HY-119398
    Lanuginosine 23740-25-2 98.27%
    Lanuginosine (Compound 12) is an AChE inhibitor (IC50: 10.9 μM). Lanuginosine inhibits Aβ aggregation. Lanuginosine can be used for research of Alzheimer’s disease.
    Lanuginosine
  • HY-119404
    Diproqualone 36518-02-2 98%
    diproqualone is methaqualone analogous with sedative, anxiolytic, anti-inflammatory and analgesic properties.
    Diproqualone
  • HY-119409
    Levophacetoperane 24558-01-8 98%
    Levophacetoperane (Phacetoperane free base) competitively inhibits the uptake of norepinephrin and dopamine.
    Levophacetoperane
  • HY-119426
    Dexamisole 14769-74-5 98%
    Dexamisole has R configuration that has a role as an antidepressant.
    Dexamisole
  • HY-119460
    Cuspin-1 337932-29-3 98%
    Cuspin-1 is a upregulator of Survival of Motor Neuron protein (SMN). Cuspin-1 upregulates SMN expression post-transcriptionally, and increases the phosphorylation of Erk. Cuspin-1 can be used for research of neurodegenerative disease, such as spinal muscular atrophy (SMA).
    Cuspin-1
  • HY-119461
    Capuride 5579-13-5 98%
    Capuride is an orally active sedative agent. Capuride has anticonvulsant activity.
    Capuride
  • HY-119463
    Trepipam 20012-08-2 98%
    Trepipam (Trimopam; SCH-12679) is a D1-dopamine receptor antagonist. Trepipam can reduce the self-injurious behavior in 6-OHDA-lesioned rats. Trepipam can be used in the research of epilepsy and anxiety neurosis.
    Trepipam
  • HY-119513
    Nizofenone 54533-85-6 98%
    Nizofenone is a neuroprotective agent which protects neurons from death following cerebral ischemia or anoxia. Nizofenone can be used in the research of acute neurological conditions, such as stroke.
    Nizofenone
  • HY-119519
    OB-2 300689-25-2 98%
    OB-2 is a STOML3 oligomerization blocker. OB-2 reverses pathological mechanical hypersensitivity. OB-2 can be used for research of painful diabetic neuropathy in mice.
    OB-2
  • HY-119552
    Acetylaszonalenin 42230-55-7 98%
    Acetylaszonalenin, a prenylated indole derivative, is a fungal metabolite.Acetylaszonalenin is a potent neurokinin-1 (NK1) receptor antagonist. Acetylaszonalenin shows inhibition of [3H]-SP binding to human astrocytoma cells with a Ki of 170 μM.
    Acetylaszonalenin
  • HY-119581
    MBED 123363-40-6 98%
    MBED (9-Methyl-7-bromoeudistomin D) is a RyR agonist. MBED is a high-affinity caffeine-like probe, helps identify the caffeine-binding site in RyRs.
    MBED
Cat. No. Product Name / Synonyms Application Reactivity